Carbamazepine in Fabry's disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction

Neurology. 1989 Apr;39(4):598-600. doi: 10.1212/wnl.39.4.598.

Abstract

Seven patients with Fabry's disease and severe pain received carbamazepine (CMZ). Five of 7 patients had moderate to complete relief based upon self-assessment of pain levels. Preexisting autonomic dysfunction was exacerbated by CMZ in 2. Complications encountered were ileus, urinary retention, and gastrointestinal disturbance. Although CMZ was useful in treatment of pain, caution should be employed in this disease.

MeSH terms

  • Adult
  • Analgesia
  • Autonomic Nervous System / drug effects
  • Autonomic Nervous System / physiopathology*
  • Carbamazepine / adverse effects
  • Carbamazepine / therapeutic use*
  • Child, Preschool
  • Fabry Disease / drug therapy*
  • Fabry Disease / physiopathology
  • Humans
  • Male
  • Pain / drug therapy

Substances

  • Carbamazepine